Louis Kassa, CEO of the Hepatitis B Foundation, Blumberg Institute and PABC, congratulates John Crowley of Amicus on being named BIO president and CEO
Louis P. Kassa III, MPA, CEO of the Hepatitis B Foundation, Baruch S. Blumberg Institute and Pennsylvania Biotechnology Center (PABC), today called the choice of John F. Crowley, JD, MBA, executive chairman, Amicus Therapeutics, to be president and CEO of BIO “a brilliant decision that will produce tangible benefits to the biotech industry.”
“John Crowley is one of the most influential executives in the field of drug development and his personal story has been an inspiration to many, many people worldwide,” Kassa said. “He’s one more example of our region’s leadership in biotech, the life sciences and health care. On behalf of our three organizations, I want to congratulate John on this exciting new opportunity.”
John Crowley (left), Ron Philip (center) and Jim Greenwood
BIO describes itself as the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the U.S. and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
Crowley was a panelist at the Oct. 17 event honoring Jim Greenwood of Bucks County, who is a former Congressman and was CEO of BIO from 2005 to 2020.
Along with Crowley and Greenwood, Ron Philip, chief executive officer of Spark Therapeutics, participated in the Oct. 17 panel discussion, which was moderated by Randall N. Hyer, MD, PhD, MPH, president of the Baruch S. Blumberg Institute and CEO of Merlin Biotech.